Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib
Status:
Active, not recruiting
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II study is to evaluate the safety and effectiveness (good and bad
effects) of carfilzomib given as a 30-minute infusion and at a dose of 70 mg/m2 to treat
patients with multiple myeloma (MM), who are currently showing progressive disease
(worsening) and had progressed (did not respond to treatment) within 8 weeks of receiving
treatment with twice weekly 27mg/m2 of carfilzomib. Carfilzomib is approved by the U.S. Food
and Drug Administration (FDA) to be used only in certain U.S. patients with relapsed and
refractory multiple myeloma that have tried and failed other therapies. Carfilzomib is
considered an investigational drug for this study because the dose and regimen included in
this study are different from the FDA approved carfilzomib regimen. Carfilzomib is a type of
drug called a proteasome inhibitor. Carfilzomib is thought to work by preventing breakdown of
abnormal proteins in cells, causing the cells to die. Cancer cells are more sensitive to
these effects than normal cells. Carfilzomib has been previously given to more than 1800
people in clinical trials.